Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

  1. Langdahl, B.L.
  2. Libanati, C.
  3. Crittenden, D.B.
  4. Bolognese, M.A.
  5. Brown, J.P.
  6. Daizadeh, N.S.
  7. Dokoupilova, E.
  8. Engelke, K.
  9. Finkelstein, J.S.
  10. Genant, H.K.
  11. Goemaere, S.
  12. Hyldstrup, L.
  13. Jodar-Gimeno, E.
  14. Keaveny, T.M.
  15. Kendler, D.
  16. Lakatos, P.
  17. Maddox, J.
  18. Malouf, J.
  19. Massari, F.E.
  20. Molina, J.F.
  21. Ulla, M.R.
  22. Grauer, A.
Revista:
The Lancet

ISSN: 1474-547X 0140-6736

Any de publicació: 2017

Volum: 390

Número: 10102

Pàgines: 1585-1594

Tipus: Article

DOI: 10.1016/S0140-6736(17)31613-6 GOOGLE SCHOLAR